GSK plc (GSK) ORD GBP0.3125
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Japan to review GSK's Blenrep drug application
17 September 2024 07:12
(Sharecast News) - Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for...
-
London close: Stocks finish firmer in subdued trading
13 September 2024 16:44
(Sharecast News) - London stocks closed in positive territory on Friday, bolstered by hopes of an interest rate cut in the United States, although the gains were modest as trading remained subdued.
-
GSK to speed up development of blood cancer treatment in China
13 September 2024 07:19
(Sharecast News) - China's health authority has granted GSK's Blenrep blood cancer treatment with a so-called 'Breakthrough Therapy Designation' (BTD), which is designed to speed up...
-
GSK reports positive results from mRNA flu vaccine trial
12 September 2024 08:55
(Sharecast News) - GSK announced promising results from its phase two clinical trial for an mRNA-based seasonal flu vaccine on Thursday.
-
GSK's herpes vaccine candidate fails to meet primary efficacy objective
11 September 2024 08:47
(Sharecast News) - Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic herpes simplex virus vaccine candidate showed that the drug had...
-
GSK announces positive COPD trial results
6 September 2024 08:53
(Sharecast News) - GSK announced positive results from its phase three 'MATINEE' clinical trial on Friday, which evaluated the effectiveness of 'Nucala', or mepolizumab, in treating...
-
GSK's RSV vaccine gets expanded approval in Europe
29 August 2024 07:18
(Sharecast News) - GSK announced on Thursday that the European Commission had granted approval for Arexvy, a respiratory syncytial virus (RSV) vaccine, to be used in adults aged 50 to 59 who were at...
-
London close: Stocks slip as investors await Nvidia results
28 August 2024 15:00
(Sharecast News) - London stocks ended slightly down on Wednesday, with investors showing restraint ahead of crucial earnings from US chipmaker Nvidia.
-
Shore Capital hails "another ray of light" at GSK after Zantac litigation update
28 August 2024 10:45
(Sharecast News) - Shore Capital has reiterated its 'buy' rating on GSK after the biopharma giant's latest update about its ongoing Zantac litigation, saying that the stock's valuation is...
-
GSK upbeat on Zantac litigation development, Japan approvals
28 August 2024 07:18
(Sharecast News) - GSK announced a number of developments on Wednesday, firstly welcoming a decision from the Delaware Supreme Court to review a lower court ruling that allowed the introduction of expert...
-
GSK lung cancer drug gets FDA breakthrough designation
20 August 2024 07:22
(Sharecast News) - Pharmaceutical giant GSK announced on Tuesday that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its investigational drug, GSK5764227...
-
London close: Stocks slip on relatively quiet Friday
16 August 2024 17:46
(Sharecast News) - London's stock markets closed lower on Friday, weighed down by a stronger pound and mixed investor sentiment following the release of the latest UK retail sales figures.
Company announcements Announcements
-
Japan Filing Acceptance: Blenrep Multiple Myeloma
17 September 2024 07:00
GSK
-
China Breakthrough Therapy Designation for Blenrep
13 September 2024 07:00
GSK
-
Director/PDMR Shareholding
12 September 2024 15:30
GSK
-
Positive mRNA flu vaccine Phase II headline data
12 September 2024 07:00
GSK
-
Statement: Zantac (ranitidine) litigation
11 September 2024 17:27
GSK
-
Change of Registered Office
11 September 2024 15:30
GSK
-
Update on phase I/II therapeutic HSV vaccine trial
11 September 2024 07:00
GSK
-
Depemokimab late-breaking data presented at ERS
9 September 2024 14:30
GSK
-
Director/PDMR Shareholding
6 September 2024 15:30
GSK
-
Positive Phase III results for Nucala in COPD
6 September 2024 07:00
GSK
-
Total Voting Rights
2 September 2024 15:00
GSK
-
EMA approval on Arexvy for 50-59 at risk
29 August 2024 07:00
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.